Market access update
The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia
With transformative treatments that leverage CRISPR gene-editing technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top-20 pharma company, multiple patients, and our own market access experts for their insights into the process, obstacles, and opportunities for biopharmaceutical companies to meet patient needs and achieve success in the market.
Download the free article to:
- Access expert opinions and find out how commercialization of novel gene-editing technology in beta-thalassemia could transform patients’ lives with a connected approach that anticipates obstacles and incorporates patient perspectives upfront
- Gain insight into the process, obstacles, and opportunities for biopharmaceutical companies to meet patient needs and achieve success in the market
- Discover how CRISPR technology could offer a safer, more accessible, and life-changing method of gene therapy for patients with beta-thalassemia if pricing is within reach
FREE Article
The promised land of gene therapy
The data you submit here will be processed by us, and our partners within Fishawack Health, as outlined in our privacy policy, cookie policy, and terms and conditions.
Latest insights
